



ABN 53 075 582 740

ASX ANNOUNCEMENT

14 November 2018

Bionomics Limited (ASX:BNO, OTCQX: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed both resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 12 October 2018.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy Votes			
			For	Against	Abstain	Proxy's discretion
1	Adoption of Remuneration Report	Carried as an ordinary resolution on a Poll	75,824,341	46,099,860	45,775,425	450,481
2	Re-election of Non-Executive Director – Mr David Wilson	Carried as an ordinary resolution on a Poll	154,775,809	12,928,085	564,848	467,481

Resolution Number	Resolutions	Result	Poll Results		
			For	Against	Abstain
1	Adoption of Remuneration Report	Carried as an ordinary resolution on a Poll	78,523,572	46,479,971	48,887,260
2	Re-election of Non-Executive Director – Mr David Wilson	Carried as an ordinary resolution on a Poll	163,678,268	12,938,085	571,558

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen

CEO

+61 8 8354 6101

drathjen@bionomics.com.au

Mr Jack Moschakis

Legal Counsel & Company Secretary

+61 8 8354 6181

jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au